Revolution Medicines, Inc. (RVMD) Tops Q3 EPS by 200c

Revolution Medicines, Inc. (NASDAQ: RVMD) reported Q3 EPS of $0.99, $2.00 better than the analyst estimate of ($1.01). Revenue for the quarter came in at $0 versus the consensus estimate of $750 thousand.

For earnings history and earnings-related data on Revolution Medicines, Inc. (RVMD) click here.

You May Also Be Interested In

• Tesla to launch Cybercab in Austin this month - report
• CalPrivate Bank names Andra Frazier as chief credit officer
• Duos Technologies Group, Inc. (DUOT) Tops Q2 EPS by 163c